vimarsana.com

Page 2 - தேசிய ப்ரைமேட் ஆராய்ச்சி மையம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

SNPRC at Texas Biomed awarded $37 million NIH grant to continue operations into 2026

SNPRC at Texas Biomed awarded $37 million NIH grant to continue operations into 2026 The Southwest National Primate Research Center (SNPRC) at Texas Biomedical Research Institute (Texas Biomed) has been awarded more than $37 million from the National Institutes of Health (NIH) to continue operations into 2026. The P51 grant, given by the NIH Office of Research Infrastructure Programs, provides essential funding to house and care for nearly 2,500 non-human primates that are part of life-science research programs at Texas Biomed and partners around the globe. Non-human primates play an essential role in pre-clinical research, including most recently helping to show that the Pfizer-BioNTech COVID-19 vaccine would be safe and effective for humans, accelerating the clinical trials. The support from NIH for our Center will ensure that we can continue this critical work in finding new treatments and vaccines against a variety of infectious diseases, while maintaining the absolute highest

Government allocates B2 8bn for COVID-19 vaccine Research and Development

Govt injects B2 8bn for domestic vaccine development push

New combination immunotherapy plus ART expand innate cells critical to controlling HIV

Yerkes NPRC/Emory University and Institut Pasteur researchers have determined adding a combination immunotherapy to antiviral therapy (ART) is effective in generating highly functional natural killer (NK) cells that can help control and reduce simian immunodeficiency virus (SIV) in animal models. This finding is key for reducing reliance on ART and developing additional treatment options to control HIV/AIDS.

Texas Biomed shares critical work in development of Pfizer COVID-19 vaccine

 E-Mail (Media note: Interviews with Texas Biomed researchers are available with advanced notice. Photos and video of rhesus macaques and the Biosafety Level 3 & 4 laboratories at Texas Biomed are available upon request.) SAN ANTONIO (April 27, 2021) - When the world was coming to grips with an emerging global pandemic a year ago, scientists at Texas Biomedical Research Institute sprang into action. The rhesus macaques at the Southwest National Primate Research Center (SNPRC) at Texas Biomed were quickly validated as models for studying vaccines designed to protect humans against SARS-CoV-2, the virus that causes COVID-19. The Pfizer-BioNTech COVID-19 vaccine was tested in this model at the Institute and has now been given to millions of people around the world.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.